MS3-2 TREATMENT STRATEGY BASED ON THE RESULTS OF GENE PANELS

• Published in: Neuro-Oncology Advances Vol. 1; no. Supplement_2; p. ii3
• Main Author: Takeda, Masayuki
• Format: Journal Article
• Language: English; Japanese
• Published: US Oxford University Press (OUP) 16.12.2019; Oxford University Press
• Subjects: Abstracts
• ISSN: 2632-2498; 2632-2498
• DOI: 10.1093/noajnl/vdz039.012

The advance of next-generation sequencers (NGS) has dramatically improved the performance of genomic analysis of clinical samples in cancer precision medicine. The practical use of gene panel testing for clinical applications has begun in Japan. At present, “OncomineTM Dx Target Test” is listed as a companion diagnostic system using NGS, and “FoundationOne CDx Cancer Genomic Profile” and “OncoGuide™ NCC Oncopanel System” are listed as gene panel testing under insurance coverage. Formalin-fixed paraffin-embedded specimen have been routinely used for molecular diagnosis testing, therefore quality control such as formalin fixation time and tumor contents is important to ensure validity of diagnostic results. In this presentation, the issue to obtain evaluable results of gene panel testing using formalin-fixed paraffin-embedded specimen will be discussed. Due to evolution of detection technologies, we can detect gene mutation with high sensitivity. Detection of gene mutation in circulating tumor DNA is feasible approach for diagnostic testing in cancer treatment. Liquid biopsy has been approved as a companion diagnostic testing to detect EGFR mutations in NSCLC. Examples of the clinical utility of plasma testing in cancer treatment will be presented.